Optometry360 Logo White
  • Conferences
  • Videos
  • Podcasts
  • Quizzes
  • About
    • About Us – Mission
    • Content Awards
    • Media Partners
    • Business Team
    • Brand Ambassadors
    • Industry Council
    • Advisory Board

What are you looking for?

  • Anterior Segment
  • Cataract
  • Cornea and External Disease
  • Diabetic Macular Edema
  • Dry Eye
  • Early Onset Cataracts
  • Exclusives
  • General
  • Geographic Atrophy
  • Glaucoma
  • Industry News
  • Inherited Retinal Disease
  • IOLs
  • Neurotrophic Keratitis
  • Ocular Surface Disease
  • Oculoplastics
  • Optometry
  • Pediatrics
  • Practice Management
  • Presbyopia
  • Refractive Surgery/Vision Correction
  • Residents & Young Ophthalmologists
  • Retina
  • Retina Care 360
  • Retinopathy of Prematurity
  • Spotlight Series
  • The Interventional Glaucoma Project
  • The Ophthalmic Project
  • Trending Topics
Spotlight - The Future of Cryopreserved Amniotic Membrane in Oculoplastic Surgery
Optometry360 Logo White
  • Conferences
  • Videos
  • Podcasts
  • Quizzes
  • About
    • About Us – Mission
    • Content Awards
    • Media Partners
    • Business Team
    • Brand Ambassadors
    • Industry Council
    • Advisory Board
Home > Refractive Surgery/Vision Correction > FDA approves next-generation presbyopia-correcting IOLs
  • Presbyopia

FDA approves next-generation presbyopia-correcting IOLs

Ophthalmology 360
FDA grants breakthrough therapy designation for ALK-001 for Stargardt Disease

The U.S. Food and Drug Administration has approved Tecnis Synergy and Tecnis Synergy Toric II IOLs (Johnson & Johnson Vision), according to a press release.

According to a company-sponsored study, 9 out of 10 patients who received the IOL lenses did not need glasses after surgery.

“The Tecnis Synergy IOL combines the best of extended depth of focus and multifocal technologies – to deliver the widest range of continuous vision with the best near vision among leading [presbyopia-correcting intraocular lens], without the visual gaps caused by existing trifocal technology,” said Rajesh Rajpal, Chief Medical Officer and Global Head of Clinical and Medical Affairs at Johnson & Johnson Vision in the press release. “Additionally, we’ll offer Tecnis Synergy IOL on our new Toric II platform, when it launches later this year, to give surgeons the ability to address astigmatism at the time of surgery.”

Read the full press release here.

Share

Related Content

  • Cataract

Spotlight on TECNIS Odyssey™

  • Cataract

IOL exchange shows highest success for dissatisfaction after presbyopia-correcting lens surgery

  • Conference Roundup

OmniVu modular shape-changing IOL offers stable refraction and sustained improvement in near vision

  • Conference Roundup

How depth of field IOL technologies can provide tolerance to refractive error

  • Refractive Surgery/Vision Correction

First-in-human study underway for non-invasive vision correction technology

  • Presbyopia

Presbyopia-correcting IOL impresses patients

Share

Editor's Picks

  • Neurotrophic Keratitis

Topical insulin shows real-world benefit in neurotrophic keratopathy

  • Retina

GLP-1 RAs have protective effects against AMD

  • Retina

Four-month injection intervals appear safe for long-term stable nAMD

Advisory Board

Saad Ahmad, MD

Ahmad A. Aref, MD, MBA

Roomasa Channa, MD

David Chow, MD, FRCS(C)

Sally L. Baxter, MD, MSc

Neel R. Desai, MD

Nadia Haqqie, MD

Simon Fung, MD, FRCOphth

Sumit Garg, MD

Ross Lakhanpal, MD, FACS

Sanjai Jalaj, MD

Anton Kolomeyer, MD, PhD

Shan Lin, MD

Steven R. Sarkisian, Jr., MD

See All
Optometry360 Logo

Ophthalmology 360® is a dynamic digital platform dedicated to advancing the field of eye care.

Get to Know Us

  • Home
  • About Us
  • Media Partners
  • Advertising Policy
  • Our Advisory Board

Sign up for our Newsletter

Sign up for our Newsletter to get our newest articles instantly!

  • Privacy Policy
  • Advertising Policy
  • Medical Disclaimer
IHM Logo

2026 Ophthalmology 360 is a trademark of International Healthcare Media, LLC. All rights reserved

  • MedJournal360 Icon
  • RareDisease360 Icon
  • MyHero360 Icon
  • Optometry360 Icon
  • Ophtalmology360 Icon